Company record
Chengdu Brilliant Biopharmaceutical Co., Ltd.
1 FDA warning letter since 2023 and 0 recalls in the last 12 months.
Get an email the day FDA posts anything new about Chengdu Brilliant Biopharmaceutical Co., Ltd..
Warning letters
-
DrugsChengdu Brilliant Biopharmaceutical Co., Ltd.
FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.
High risk